Drug
AZD1390
AZD1390 is a pharmaceutical drug with 5 clinical trials. Currently 5 active trials ongoing.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
5(100%)
Phase Distribution
Ph phase_2
1
20%
Ph early_phase_1
1
20%
Ph phase_1
3
60%
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
5
trials recruiting
Total Trials
5
all time
Status Distribution
Active(5)
Detailed Status
Recruiting3
Active, not recruiting2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
5
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (20.0%)
Phase 13 (60.0%)
Phase 21 (20.0%)
Trials by Status
active_not_recruiting240%
recruiting360%
Recent Activity
5 active trials
Showing 5 of 5
recruitingphase_2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NCT03970447
active_not_recruitingearly_phase_1
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
NCT05182905
recruitingphase_1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
NCT03423628
recruitingphase_1
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
NCT04550104
active_not_recruitingphase_1
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
NCT05678010
Clinical Trials (5)
Showing 5 of 5 trials
NCT03970447Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NCT05182905Early Phase 1
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
NCT03423628Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
NCT04550104Phase 1
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
NCT05678010Phase 1
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5